Combined Surgical Techniques for the Management of Malignant Glaucoma

Table 1

Preoperative and postoperative summary of the 9 eyes.

Patient number	Age (year)	Sex	Eye	Axial length (mm)	History	BCVA		IOP (mmHg)		Anterior chamber depth (mm)		Medications		Follow-up (months)	Complications	Recurrence
						Pre-op	Post-op	Pre-op	Post-op	Pre-op	Post-op	Pre-op	Post-op
1	82	M	R	20.41	LPI, P	20/60	20/60	28	17	2.14	3.05	a, b	0	12	No	No
	82	M	L	20.50	LPI	20/200	20/40	18	13	1.55	3.16	0	0	12	No	No
2	42	F	L	21.71	PACG, T	20/40	20/25	38	13	2.30	2.92	a, b, c	0	9	No	No
	42	F	R	21.82	PACG	LP	HM	43	20	2.00	2.80	b, c	0	9	No	No
3	71	F	L	20.58	PACG, P, T	20/80	20/80	21	17	2.03	3.07	a, b	0	10	No	No
	71	F	R	20.55	PACG, P	20/40	20/30	23	12	1.50	3.21	a, b	0	10	No	No
4	60	M	R	22.87	P	20/200	20/200	31	22	2.30	2.86	a, b	b	3	No	No
5	59	F	L	21.49	P	20/200	20/30	46	18	1.68	3.20	a, b	0	3	No	No
6	65	F	R	22.44	Narrow angle, LPI, P	20/30	20/30	25	15	1.83	2.94	a	0	6	No	No

M, male; F, female; P, phaco; T, trabeculectomy; PACG, primary angle closure glaucoma; R, right; L, left; LPI, laser peripheral iridotomy; HM, hand movement; LP, light perception. a = mydriatics and cyloplegics; b = topical antiglaucoma medications; c = oral carbonic anhydrase inhibitors.